Fulcrum Therapeutics Inc. (FULC)
NASDAQ (NMS) NASDAQ (NMS) Primary Summary
Fulcrum Therapeutics (FULC) Loses 51% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
The heavy selling pressure might have exhausted for Fulcrum Therapeutics (FULC) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
FULC Stock Crashes as Cancer Risk Forces Its Only Drug Program's End
Fulcrum Therapeutics stock sinks 51% after ending pociredir development in SCD due to FDA cancer-risk concerns, leaving no clinical-stage assets.
Fulcrum scraps sickle cell drug program after FDA raises cancer-risk concerns
Fulcrum Therapeutics said on Monday it would stop developing its experimental sickle-cell disease drug after the U.S. Food and Drug Administration raised cancer-risk concerns, which left no viable regulatory path for the treatment.
Fulcrum Therapeutics Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| CE Curtis Ellergodt Rothschild Investment LLC | 8 | $90 | $28.46 | -$61.54 | -68.38% |
| BG Bart Gancher Intech Investment Management LLC | 13,242 | $59,237.25 | $46,810.47 | -$12,426.78 | -20.98% |
 Point72 Asset Management LP Point72 Asset Management LP | 2.07M | $23.47M | $7.36M | -$16.11M | -68.64% |
| PF Phillip Fitzsimmons Hennion & Walsh Asset Management Inc. | 233,851 | $872,264.23 | $829,539.65 | -$42,724.58 | -4.9% |
 Joseph Castro Nuveen LLC | 129,618 | $456,717.71 | $459,495.81 | $2,778.1 | 0.61% |
Fulcrum Therapeutics Inc. Analysts
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
 Edward Tenthoff Piper Sandler | -2,793.3 | $10,083.8 | $9,944.13 | $139.67 | 1.39% |
Fulcrum Therapeutics Inc. (FULC) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Fulcrum Therapeutics Inc. ever had a stock split?
Fulcrum Therapeutics Inc. Profile
| Biotechnology Industry | Healthcare Sector | Alexander C. Sapir CEO | NASDAQ (NMS) Exchange | 359616109 CUSIP |
| US Country | 55 Employees | - Last Dividend | - Last Split | 18 Jul 2019 IPO Date |
Overview
Fulcrum Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients suffering from genetically defined diseases with a significant unmet medical need. Established in 2015 with its headquarters located in Cambridge, Massachusetts, Fulcrum Therapeutics is at the forefront of developing innovative therapies. The company’s strategic focus lies in addressing rare neuromuscular, muscular, central nervous system, hematologic disorders, cardiomyopathies, and pulmonary diseases. Collaborating with industry leaders such as Acceleron Pharma Inc. and MyoKardia, Inc., Fulcrum is pushing the boundaries in drug discovery and development to modulate specific biological pathways for various targeted indications.
Products and Services
- Losmapimod:
- Pociredir:
- Drug Discovery for Rare Diseases:
A pioneering small molecule in phase III clinical trial specifically designed for the treatment of facioscapulohumeral muscular dystrophy. Losmapimod represents Fulcrum Therapeutics’ commitment to addressing the challenges in neuromuscular diseases by targeting the underlying genetic causes.
Identified as a fetal hemoglobin inducer presently in phase I clinical trial. Pociredir aims to provide a groundbreaking treatment for sickle cell disease and beta-thalassemia. By focusing on these blood disorders, Fulcrum is moving towards fulfilling the urgent need for new, effective treatments for these life-altering conditions.
In addition to its clinical trials for losmapimod and pociredir, Fulcrum Therapeutics is actively engaged in the discovery of drug targets for the treatment of a variety of rare disorders. These include neuromuscular, muscular, central nervous system, and hematologic disorders, along with genetic cardiomyopathies and pulmonary diseases. This effort underscores Fulcrum’s comprehensive approach to tackling complex, rare diseases by exploring and developing new therapeutic pathways.
